In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020
Background/purpose: This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparativ...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | Journal of Microbiology, Immunology and Infection |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1684118221001869 |
| _version_ | 1798030959428239360 |
|---|---|
| author | Po-Yu Liu Wen-Chien Ko Wen-Sen Lee Po-Liang Lu Yen-Hsu Chen Shu-Hsing Cheng Min-Chi Lu Chi-Ying Lin Ting-Shu Wu Muh-Yong Yen Lih-Shinn Wang Chang-Pan Liu Pei-Lan Shao Yu-Lin Lee Zhi-Yuan Shi Yao-Shen Chen Fu-Der Wang Shu-Hui Tseng Chao-Nan Lin Yu-Hui Chen Wang-Huei Sheng Chun-Ming Lee Hung-Jen Tang Po-Ren Hsueh |
| author_facet | Po-Yu Liu Wen-Chien Ko Wen-Sen Lee Po-Liang Lu Yen-Hsu Chen Shu-Hsing Cheng Min-Chi Lu Chi-Ying Lin Ting-Shu Wu Muh-Yong Yen Lih-Shinn Wang Chang-Pan Liu Pei-Lan Shao Yu-Lin Lee Zhi-Yuan Shi Yao-Shen Chen Fu-Der Wang Shu-Hui Tseng Chao-Nan Lin Yu-Hui Chen Wang-Huei Sheng Chun-Ming Lee Hung-Jen Tang Po-Ren Hsueh |
| author_sort | Po-Yu Liu |
| collection | DOAJ |
| description | Background/purpose: This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparative antibiotics. Methods: In total, 405 non-duplicate bacteremic CNSPA (n = 150) and CNSAB (n = 255) isolates were collected from 16 hospitals in Taiwan between 2018 and 2020. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibilities were interpreted according to the relevant guidelines or in accordance with results of previous studies and non-species-related pharmacokinetic/pharmacodynamic data. Results: Among the isolates tested, cefiderocol demonstrated potent in vitro activity against CNSPA (MIC50/90, 0.25/1 mg/L; 100% of isolates were inhibited at ≤4 mg/L) and CNSAB (MIC50/90, 0.5/2 mg/L; 94.9% of isolates were inhibited at ≤4 mg/L) isolates. More than 80% of CNSPA isolates were susceptible to cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, and amikacin, based on breakpoints established by the Clinical and Laboratory Standards Institute. Activities of new BLI combinations varied significantly. Tetracycline analogues, including tigecycline (MIC50/90, 1/2 mg/L; 92.5% of CNSAB isolates were inhibited at ≤2 mg/L) and eravacycline (MIC50/90, 0.5/1 mg/L; 99.6% of CNSAB isolates were inhibited at ≤2 mg/L) exhibited more potent in vitro activity against CNSAB than omadacycline (MIC50/90, 4/8 mg/L). Conclusions: The spread of CNSPA and CNSAB poses a major challenge to global health. Significant resistance be developed even before a novel agent becomes commercially available. The development of on-site antimicrobial susceptibility tests for these novel agents is of great clinical importance. |
| first_indexed | 2024-04-11T19:48:32Z |
| format | Article |
| id | doaj.art-d34d33f2182440d0af50bfe0d5bbd14f |
| institution | Directory Open Access Journal |
| issn | 1684-1182 |
| language | English |
| last_indexed | 2024-04-11T19:48:32Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Microbiology, Immunology and Infection |
| spelling | doaj.art-d34d33f2182440d0af50bfe0d5bbd14f2022-12-22T04:06:22ZengElsevierJournal of Microbiology, Immunology and Infection1684-11822022-10-01555888895In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020Po-Yu Liu0Wen-Chien Ko1Wen-Sen Lee2Po-Liang Lu3Yen-Hsu Chen4Shu-Hsing Cheng5Min-Chi Lu6Chi-Ying Lin7Ting-Shu Wu8Muh-Yong Yen9Lih-Shinn Wang10Chang-Pan Liu11Pei-Lan Shao12Yu-Lin Lee13Zhi-Yuan Shi14Yao-Shen Chen15Fu-Der Wang16Shu-Hui Tseng17Chao-Nan Lin18Yu-Hui Chen19Wang-Huei Sheng20Chun-Ming Lee21Hung-Jen Tang22Po-Ren Hsueh23Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, TaiwanDepartment of Medicine, College of Medicine, National Cheng Kung University, Tainan, TaiwanDivision of Infectious Diseases, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, TaiwanDepartment of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanDepartment of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanDepartment of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan; School of Public Health, College of Public Health and Nutrition, Taipei Medical University, Taipei, TaiwanDepartment of Microbiology and Immunology, School of Medicine, China Medical University, Taichung, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, TaiwanDivision of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, TaiwanDivision of Infectious Diseases, Taipei City Hospital, National Yang-Ming University, School of Medicine, Taipei, TaiwanDivision of Infectious Diseases, Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan; Tzu Chi University, Hualien, TaiwanDivision of Infectious Diseases, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan; MacKay Medical College, New Taipei City, TaiwanDepartment of Pediatrics, Hsin-Chu Branch, National Taiwan University Hospital, Hsin-Chu, TaiwanDepartment of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung, TaiwanDepartment of Internal Medicine, Taichung Veterans General Hospital, Taichung, TaiwanDepartment of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; School of Medicine, National Yang-Ming University, Taipei, TaiwanDivision of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang-Ming University, Taipei, TaiwanCenter for Disease Control and Prevention, Ministry of Health and Welfare, TaiwanDepartment of Veterinary Medicine, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung, Taiwan; Animal Disease Diagnostic Center, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung, TaiwanInfection Control Center, Chi Mei Hospital, Liouying, TaiwanDivision of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Internal Medicine, St Joseph's Hospital, Yunlin County, Taiwan; MacKay Junior College of Medicine, Nursing, and Management, Taipei, TaiwanDepartment of Medicine, Chi Mei Medical Center, Tainan, TaiwanDivision of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Departments of Laboratory Medicine and Internal Medicine, China Medical University Hospital, School of Medicine, China Medical University, Taichung, Taiwan; Corresponding author. Department of Laboratory Medicine, China Medical University Hospital, No. 2, Yude Road, North District, Taichung 404394, Taiwan.Background/purpose: This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparative antibiotics. Methods: In total, 405 non-duplicate bacteremic CNSPA (n = 150) and CNSAB (n = 255) isolates were collected from 16 hospitals in Taiwan between 2018 and 2020. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibilities were interpreted according to the relevant guidelines or in accordance with results of previous studies and non-species-related pharmacokinetic/pharmacodynamic data. Results: Among the isolates tested, cefiderocol demonstrated potent in vitro activity against CNSPA (MIC50/90, 0.25/1 mg/L; 100% of isolates were inhibited at ≤4 mg/L) and CNSAB (MIC50/90, 0.5/2 mg/L; 94.9% of isolates were inhibited at ≤4 mg/L) isolates. More than 80% of CNSPA isolates were susceptible to cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, and amikacin, based on breakpoints established by the Clinical and Laboratory Standards Institute. Activities of new BLI combinations varied significantly. Tetracycline analogues, including tigecycline (MIC50/90, 1/2 mg/L; 92.5% of CNSAB isolates were inhibited at ≤2 mg/L) and eravacycline (MIC50/90, 0.5/1 mg/L; 99.6% of CNSAB isolates were inhibited at ≤2 mg/L) exhibited more potent in vitro activity against CNSAB than omadacycline (MIC50/90, 4/8 mg/L). Conclusions: The spread of CNSPA and CNSAB poses a major challenge to global health. Significant resistance be developed even before a novel agent becomes commercially available. The development of on-site antimicrobial susceptibility tests for these novel agents is of great clinical importance.http://www.sciencedirect.com/science/article/pii/S1684118221001869Cefepime/enmetazobactamCefepime/zidebactamCefiderocolOmadacyclineEravacycline |
| spellingShingle | Po-Yu Liu Wen-Chien Ko Wen-Sen Lee Po-Liang Lu Yen-Hsu Chen Shu-Hsing Cheng Min-Chi Lu Chi-Ying Lin Ting-Shu Wu Muh-Yong Yen Lih-Shinn Wang Chang-Pan Liu Pei-Lan Shao Yu-Lin Lee Zhi-Yuan Shi Yao-Shen Chen Fu-Der Wang Shu-Hui Tseng Chao-Nan Lin Yu-Hui Chen Wang-Huei Sheng Chun-Ming Lee Hung-Jen Tang Po-Ren Hsueh In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020 Journal of Microbiology, Immunology and Infection Cefepime/enmetazobactam Cefepime/zidebactam Cefiderocol Omadacycline Eravacycline |
| title | In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020 |
| title_full | In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020 |
| title_fullStr | In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020 |
| title_full_unstemmed | In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020 |
| title_short | In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020 |
| title_sort | in vitro activity of cefiderocol cefepime enmetazobactam cefepime zidebactam eravacycline omadacycline and other comparative agents against carbapenem non susceptible pseudomonas aeruginosa and acinetobacter baumannii isolates associated from bloodstream infection in taiwan between 2018 2020 |
| topic | Cefepime/enmetazobactam Cefepime/zidebactam Cefiderocol Omadacycline Eravacycline |
| url | http://www.sciencedirect.com/science/article/pii/S1684118221001869 |
| work_keys_str_mv | AT poyuliu invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT wenchienko invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT wensenlee invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT polianglu invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT yenhsuchen invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT shuhsingcheng invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT minchilu invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT chiyinglin invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT tingshuwu invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT muhyongyen invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT lihshinnwang invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT changpanliu invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT peilanshao invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT yulinlee invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT zhiyuanshi invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT yaoshenchen invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT fuderwang invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT shuhuitseng invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT chaonanlin invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT yuhuichen invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT wanghueisheng invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT chunminglee invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT hungjentang invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 AT porenhsueh invitroactivityofcefiderocolcefepimeenmetazobactamcefepimezidebactameravacyclineomadacyclineandothercomparativeagentsagainstcarbapenemnonsusceptiblepseudomonasaeruginosaandacinetobacterbaumanniiisolatesassociatedfrombloodstreaminfectionintaiwanbetween2018 |